| Budget Amount *help |
¥5,070,000 (Direct Cost: ¥3,900,000、Indirect Cost: ¥1,170,000)
Fiscal Year 2013: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2012: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2011: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
|
|---|
| Research Abstract |
A Phase 1/2 study of adjuvant immunotherapy using HSP70mRNA encoding dendritic cells after hepatectomy for the patients with hepatocellular carcinoma was performed. Patients were randomly assigned to DC group or surgery group. The safety and the efficacy were evaluated. First 9 patients were recruited to confirm the safety as phase 1 study. (1)Phase 1/2 study: The safety of this therapy was confirmed. All patients (DC group: 18 cases, surgery group: 8 cases) were alive, currently in progress. (2)Immunological assessment :(1)ossibility of non-specific immunoreaction in NK cells and B cells was suggested. (2)Possibility of was specific immunoreaction for HSP70 was suggested by ELISpot assay.
|
